Loading...
Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
Background: Fluticasone furoate/vilanterol (FF/V) is an effective long-acting β2 agonist/inhaled corticosteroid combination for managing persistent bronchial asthma. The aim of the study was to assess the outcomes achievable in patients with mild to moderate asthma receiving FF/V 92/22 µg once daily...
Saved in:
Main Authors: | , , |
---|---|
Format: | Artigo |
Language: | Inglês |
Published: |
SAGE Publishing
2018-09-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753466618789894 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|